JJ Meier, MA Nauck, D Kranz, JJ Holst, CF … - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are
important factors in the pathogenesis of type 2 diabetes and have a promising
therapeutic potential. Alterations of their secretion, in vivo degradation, ... Cited by 89 - Related articles - BL Direct - All 4 versions
- ►endocrinology-journals.org [PDF] VA Gault, JC Parker, P Harriott, PR Flatt, FP O … - Journal of Endocrinology, 2002 - Soc Endocrinology The incretin hormone glucose-dependent insulinotropic polypeptide (GIP) is
rapidly degraded in the circulation by dipeptidyl peptidase IV forming the
N-terminally truncated peptide GIP(3–42). The present study exam- ined ... Cited by 57 - Related articles - BL Direct - All 5 versions
- ►physiology.org JJ Meier, O Goetze, J Anstipp, D Hagemann, … - American Journal of Physiology- Endocrinology And …, 2004 - Am Physiological Soc The insulinotropic gut hormone gastric inhibitory polypeptide (GIP) has been
demonstrated to inhibit gastric acid secretion and was proposed to possess
"enterogastrone" activity. GIP effects on gastric emptying have not yet ... Cited by 56 - Related articles - BL Direct - All 4 versions
LL Kjems, JJ Holst, A Vølund, S Madsbad - Diabetes, 2003 - Am Diabetes Assoc The intestinally derived hormone glucagon-like peptide 1 (GLP-1) (7-36 amide)
has potent effects on glucose-mediated insulin secretion, insulin gene
expression, and β-cell growth and differentiation. It is, therefore, ... Cited by 139 - Related articles - BL Direct - All 5 versions
JJ Meier, B Gallwitz, N Siepmann, JJ Holst, … - Diabetologia, 2003 - Springer Aims/hypothesis. In the isolated perfused pancreas, gastric inhibitory
polypeptide (GIP) has been shown to enhance glucagon secretion at basal glucose
con- centrations, but in healthy humans no glucagonotropic effect of GIP ... Cited by 60 - Related articles - BL Direct - All 3 versions
- ►diabetica.co.uk [PDF] VA Gault, FPM O'Harte, PR Flatt - Neuropeptides, 2003 - Elsevier Glucose-dependent insulinotropic polypeptide (GIP or gastric inhibitory
polypeptide) is a gastrointestinal hormone, which modulates physiological
insulin secretion. Due to its insulinotropic activity, there has been a ... Cited by 53 - Related articles - All 10 versions
- ►endojournals.org L Hansen, CF Deacon, C Orskov, JJ Holst - Endocrinology, 1999 - Endocrine Soc Although the GLP-1 extractable from the porcine ileum is predominantly the
intact peptide (94.6 ± 1.7%), a large proportion of the GLP-1 that is secreted
has already been degraded to the truncated form both in vitro (53.8 ± 0.9% ... Cited by 135 - Related articles - BL Direct - All 4 versions
JG Kim, LL Baggio, DP Bridon, JP Castaigne, … - Diabetes, 2003 - Am Diabetes Assoc The rapid degradation of native glucagon-like peptide 1 (GLP-1) by dipeptidyl
peptidase-IV (DPP-IV) has fostered new approaches for generation of
degradation-resistant GLP-1 analogues. We examined the biological activity ... Cited by 126 - Related articles - BL Direct - All 5 versions
C Ruiz-Grande, C Alarcon, A Alcantara, C … - Hormone and metabolic research, 1993 - thieme-connect.com We have searched for the contribution of the kidney to the catabolism of
glucagon-like peptide-1 (7-36)amide or tGLP-1 by analyzing the disappearance of
the [ 125 I]tGLP-1 both in vivo, from the plasma of bilaterally ... Cited by 46 - Related articles - BL Direct - All 3 versions
JJ Meier, B Gallwitz, B Kask, CF Deacon, JJ … - Diabetes, 2004 - Am Diabetes Assoc A reduced insulinotropic effect of gastric inhibitory polypeptide (GIP) is a
characteristic of patients with type 2 diabetes. It was the aim of this study to
determine the response of insulin secretion to different GIP doses ... Cited by 41 - Related articles - BL Direct - All 4 versions
